by John Conrad | Jun 8, 2026 | iBIO in the News, iBIO News
Chicagoland has earned a spot on Genetic Engineering & Biotechnology News’ annual ranking of the Top 10 U.S. Biopharma Clusters, a recognition that reflects the region’s growing momentum across research, investment, and industry expansion. GEN ranks clusters...
by John Conrad | Jun 1, 2026 | iBIO News
For a decade, iBIO STEMgirls has been turning curious girls into confident innovators across the country. Hands-on experiments. Real STEM professionals in the room. Confidence-building challenges designed to flip the question from “Can I do this?” to...
by John Conrad | Jun 1, 2026 | iBIO News, Policy News
The passage of HB 4327 is a significant and long-overdue win for transparency, accountability, and — most importantly — for Illinois patients. For the first time, Illinois will have an independent, standardized accounting of how the 340B program actually operates in...
by John Conrad | May 27, 2026 | iBIO in the News, Policy News
Yesterday in Springfield, iBIO President and CEO John Conrad testified on legislation that would expand and reshape how Illinois interacts with the federal 340B drug discount program—underscoring a principle iBIO believes must come first: independent, enforceable...
by John Conrad | May 15, 2026 | Policy News
CHICAGO — The Illinois Biotechnology Innovation Organization (iBIO) today responded to a May 12, 2026 memorandum from the Illinois Department of Central Management Services (CMS) — the state agency that administers the State Employees Group Insurance Program (SEGIP) —...
